Brimonidine efficiency and tolerability in patients with glaucoma

Abstract

Background. The preparation of the new class - selective α₂-adrenoceptor agonists “Alphagan P” (Brimonidinum 0.15 %) come into to the Russian pharmaceutical market in 2012 Methods. Clinical evaluation of the “Alphagan P” eye drops efficiency in the protocol of treatment of 36 patients with primary open-angle glaucoma for the period of 12 months. Results. The drug effectively decrease intraocular pressure. During the period of investigation visual functions remain stable. With the “Alphagan P” appointing to the patients with concomitant somatic diseases were not registered significant local and systemic side effects. Conclusions. “Alphagan P” for the stabilization of the glaucomatous process in the early stages could be used as the monotherapy agent, and on the far-advanced stage - in combination with standart drugs (analogue of prostaglandin and β-blocker).